查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842112

全球下一代癌症診斷市場：市場規模、佔有率和趨勢分析（按技術、應用、癌症類型、功能和地區分類），細分市場預測（2025-2033 年）

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 138 Pages | 商品交期: 2-10個工作天內

價格

下一代癌症診斷：市場概覽

全球下一代癌症診斷市場預計到 2024 年將達到 166.1 億美元，到 2033 年將達到 414.4 億美元，2025 年至 2033 年的複合年成長率為 11.15%。

預計該行業的成長將受到以下因素的推動：腫瘤疾病的日益普遍、對各種癌症進行有效預後和早期診斷的需求，以及主要企業為滿足日益成長的高效診斷需求而開發創新解決方案的舉措。

傳統上，癌症診斷涉及多項檢查，包括身體檢查、實驗室影像檢查和切片檢查。常規診斷流程的每一步，以及腫瘤科醫師所做的預後和治療方法決策，都遵循一套明確的流程以避免潛在的併發症。這凸顯了診斷在腫瘤治療整個生命週期中的關鍵作用，其重要性甚至超過了治療方法。

次世代定序(NGS) 已成為腫瘤診斷領域的變革性力量，能夠對腫瘤進行全面的基因組分析，並將患者與標靶治療相匹配。透過識別可操作的突變和分子改變，NGS 支持個人化醫療策略，從而改善臨床療效。然而，定序在常規診療中的作用仍需更清晰的證據分層，因為並非所有攜帶可操作突變的患者最終都能接受標靶治療。諸如診療流程中定序時機的選擇、醫生解讀、定序的可及性有限以及成本效益等障礙，仍然限制著定序技術的更廣泛應用。

諸如TAPUR研究和NCI MATCH研究等大型舉措旨在產生關於定序序列主導的治療選擇影響的可靠真實世界證據。儘管美國醫療保險和醫療補助服務中心（CMS）的國家醫療保險覆蓋範圍決定（NCDC）透過核准FoundationOne CDx（F1CDx）等檢測擴大了醫療服務的可及性，但取消「基於證據開發的申請」要求引發了人們對持續追蹤治療結果的呼籲，包括總生存期、無惡化生存期和緩解率等指標。批評者認為，更全面的檢測組合（如F1CDx）可能會增加成本，但未必能帶來相應的臨床獲益，NCI MATCH研究中某些標靶治療組的緩解率較低就證明了這一點。這凸顯了對基於序列定序的治療方法進行更多循證檢驗的必要性。

除了基因組學之外，該領域正迅速向多體學整合發展。 DNA 提供了一個靜態的藍圖，而 RNA 定序（轉錄組學）和蛋白質組學（質譜分析）等互補方法則提供了基因表現和蛋白質訊號路徑動態變化的見解。結合代謝體學，這些資料層能夠描繪出腫瘤生物學的整體情況圖像。諸如 TCGA 之類的計劃凸顯了整合體學的潛力，但如何將這些資料集整合為具有臨床指導意義的結果仍然面臨挑戰。

同時，各公司正加速這些技術的臨床應用。 2025年5月，Illumina公司推出了TruSight Oncology (TSO) Comprehensive試劑盒，進一步拓展了其腫瘤產品組合。該套件是首個獲得FDA核准的、可商用的CGP體外診斷試劑套件，具備泛癌伴隨診斷（CDx）功能，目前已納入Medicare和大多數商業保險的報銷範圍。該檢測涵蓋500多個基因，並已獲得日本監管機構的核准，目前正在社區醫院和學術中心進行臨床應用。 Illumina公司也深化了與Pillar Biosciences公司的合作，將oncoReveal® CDx panel添加到MiSeq Dx系統中，進一步普及了自體腫瘤基因譜分析。同樣，2025年6月，QIAGEN和Incyte公司啟動合作，共同開發用於骨髓增生性腫瘤的多模態NGS伴隨診斷試劑盒。此檢測可檢測 mutCALR 突變，並支持 Incyte 公司針對原發性血小板增多症和骨髓纖維化的創新抗體計畫 (INCA033989)。 2025 年 3 月，GenomOncology 與 Chronetyx Laboratories 合作，透過整合其病理工作台軟體與 Chronetyx 已獲 FDA已通過核准、CE-IVD 認證的 Cyx Solid Tumor 505 檢測，簡化臨床應用流程，實現三級分析自動化，並顯著縮短 NGS 結果的周轉時間。這些舉措共同凸顯了領導企業如何解決報銷、工作流程自動化和生物標記擴展的瓶頸，從而加速精準腫瘤學的普及應用。

二代定序（NGS）在腫瘤免疫診斷中也扮演核心角色。腫瘤突變負荷（TMB）、PD-L1表現和新抗原譜分析正日益被用作免疫查核點抑制劑療效的生物標記。晚期肝細胞癌（HCC）的證據表明，TP53突變與存活期延長有關，而TERT和BRD4突變則預示著預後不良。EXOME顯子序列測定和蛋白質體學的結合有助於識別主要組織相容性複合體（MHC）呈現的新抗原，指南個別化免疫治療策略。

液態切片和單細胞定序等新興診斷方法正在進一步塑造市場格局。液態切片能夠非侵入性檢測循環腫瘤DNA（ctDNA），並即時監測治療抗藥性；而單細胞定序能揭示腫瘤內異質性，並識別可能驅動抗藥性和轉移的亞克隆。這些技術共同克服了傳統組織切片檢查的關鍵局限性，並有望加速精準腫瘤學的普及應用。

人工智慧 (AI) 和機器學習 (ML) 的融合是推動這些進步的重要因素。這些工具能夠分析大量大量的大量定序 (NGS) 和多組體學資料集，並揭示隱藏的關聯性，從而為預測建模、治療選擇和抗藥性機制的研究提供資訊。人工智慧增強的生物資訊流程有望提高診斷準確性、縮短週轉時間並最佳化臨床決策，使其成為下一代癌症診斷市場的關鍵成長驅動力。

然而，仍有許多挑戰。並非所有檢測到的突變都具有臨床意義，許多突變處於灰色地帶，其臨床效用尚不清楚。圍繞著意外發現、患者知情同意和資料隱私等倫理問題，進一步增加了技術應用的複雜性。標準化指南、更完善的證據框架以及腫瘤學家、遺傳學家、生物資訊學家和倫理學家之間的多學科合作，對於充分發揮新一代定序（NGS）及相關技術的潛力至關重要。

整體而言，市場正從單一模式的基因組分析朝向整合的、人工智慧驅動的多組體學解決方案演進。 Illumina公司獲得FDA核准的CGP檢測、QIAGEN公司專注於血液學的伴隨診斷以及GenomOncology公司的工作流程自動化夥伴關係進展，加上液態切片和免疫腫瘤生物標記的廣泛應用，為該領域的顯著成長奠定了基礎。然而，其長期發展軌跡將取決於能否在真實臨床環境中展現出明確的臨床效用、成本效益以及改善患者預後的效果。

目錄

第1章：下一代癌症診斷市場：分析方法和範圍

第2章：下一代癌症診斷市場：執行摘要

  • 市場概述
  • 技術與應用：簡介
  • 癌症類型和功能：概覽
  • 競爭格局概覽

第3章：下一代癌症診斷市場：促進因素、趨勢和範圍

  • 市場區隔及範圍
  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
    • 基因定序的成本正在呈指數級下降。
    • 叢集晶片技術的發展及其在癌症治療的潛在應用
    • 對預防醫學和伴隨診斷的需求日益成長
    • 癌症發生率增加
  • 市場限制因素分析
    • 需要昂貴的實驗室設備來進行新的測試
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章：下一代癌症診斷市場：按技術分類的估計和趨勢分析

  • 下一代癌症診斷市場：按技術分類的差異分析
  • 次世代定序
  • qPCR，多重PCR
  • LOAC，RT-PCR
  • 蛋白質微陣列
  • DNA微陣列

第5章：下一代癌症診斷市場：按應用分類的估計和趨勢分析

  • 下一代癌症診斷市場：按應用分類的波動分析
  • 生物標記開發
  • CTC分析
  • 蛋白質體分析
  • 表觀遺傳分析
  • 基因分析

第6章：下一代癌症診斷市場：按癌症類型分類的估計和趨勢分析

  • 下一代癌症診斷市場：按癌症類型分類的波動分析
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 其他

第7章 下一代癌症診斷市場：按功能分類的估計和趨勢分析

  • 下一代癌症診斷市場：按功能分類的差異分析
  • 治療監測
  • 伴隨診斷
  • 預後
  • 癌症篩檢
  • 風險分析

第8章：下一代癌症診斷市場：按地區分類的業務分析

  • 區域市場概覽
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品上市
    • 夥伴關係
    • 企業收購
    • 商業夥伴關係
    • 資金籌措
  • 主要企業市佔率分析（2024 年）
  • 公司熱力圖分析
  • 公司簡介
    • JANSSEN PHARMACEUTICALS, INC.
    • NOVARTIS AG
    • F. HOFFMANN-LA ROCHE LTD
    • KONINKLIJKE PHILIPS NV
    • ABBOTT
    • GE HEALTHCARE
    • THERMO FISHER SCIENTIFIC, INC.
    • AGILENT TECHNOLOGIES, INC.（DAKO）
    • ILLUMINA, INC.
    • QIAGEN
    • CEPHEID
    • OPKO HEALTH, INC.
    • HOLOGIC, INC（GEN-PROBE）
    • PERKINELMER INC.
    • SYSMEX
    • MYRIAD GENETICS, INC.
    • ALMAC GROUP
    • EXOSOME DIAGNOSTICS, INC.
    • GENOMIC HEALTH, INC.
Product Code: 978-1-68038-738-4

Next Generation Cancer Diagnostics Market Summary

The global next generation cancer diagnostics market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 41.44 billion by 2033, growing at a CAGR of 11.15% from 2025 to 2033. The growth of the industry is anticipated to be driven by the rising incidence of oncology diseases, the need for efficient prognosis and early diagnosis of various forms of cancer, and rising initiatives by key players in the development of innovative solutions to meet the rising demand for efficient diagnostics.

Several tests, including physical examination, laboratory tests, imaging tests, and biopsy, have traditionally been performed in cancer diagnosis. Each step of the usual diagnostic procedure, with the prognosis and therapeutic decision made by oncologists, comes with a well-defined approach to avoid potential complications. This highlights the crucial importance of diagnosis throughout the entire oncology lifecycle, surpassing the therapeutic regimen's significance.

Next-generation sequencing (NGS) has become a transformative force in oncology diagnostics, enabling comprehensive genomic profiling of tumors to match patients with targeted therapies. By identifying actionable mutations and molecular alterations, NGS supports personalized medicine strategies that improve clinical outcomes. However, the impact of sequencing in routine care still requires clearer evidence stratification, as not all patients with actionable mutations ultimately receive targeted therapies. Barriers such as the timing of sequencing within the care pathway, physician interpretation, limited accessibility, and cost-effectiveness continue to restrict broader adoption.

Large-scale initiatives such as the TAPUR Study and the NCI MATCH Study aim to generate robust real-world evidence on the impact of sequencing-driven treatment selection. While CMS's National Coverage Determination expanded access by approving tests like FoundationOne CDx (F1CDx), the removal of the "coverage with evidence development" requirement has amplified calls for continuous outcome tracking, including metrics such as overall survival, progression-free survival, and response rates. Critics argue that broader panels (such as F1CDx) may add costs without always providing proportional clinical benefit, as illustrated by modest response rates in certain targeted therapy arms of NCI MATCH. This underscores the need for more evidence-based validation of sequencing-guided treatment approaches.

Beyond genomics, the field is rapidly expanding toward multi-omics integration. While DNA provides a static blueprint, complementary approaches such as RNA sequencing (transcriptomics) and proteomics (mass spectrometry) offer dynamic insights into gene expression and protein signaling pathways. Combined with metabolomics, these data layers create a holistic picture of tumor biology. Projects like TCGA have highlighted the promise of integrated-omics, though challenges remain in harmonizing these datasets into clinically actionable outputs.

At the same time, companies are accelerating the clinical deployment of such technologies. In May 2025, Illumina expanded its oncology portfolio with the launch of TruSight Oncology (TSO) Comprehensive, the first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims, which is now reimbursed under Medicare and most commercial plans. The test, covering more than 500 genes, has also gained regulatory approval in Japan and is being integrated into clinical practice across community hospitals and academic centers. Illumina also deepened its partnership with Pillar Biosciences, adding the oncoReveal(R) CDx panel on the MiSeq Dx System, further democratizing access to in-house tumor profiling. Similarly, in June 2025, QIAGEN and Incyte entered a collaboration to develop a multimodal NGS companion diagnostic for myeloproliferative neoplasms, validated on the Illumina NextSeq 550Dx platform. The test will detect mutCALR mutations, supporting Incyte's innovative antibody program (INCA033989) for essential thrombocythemia and myelofibrosis. In March 2025, GenomOncology partnered with Chronetyx Laboratories to streamline clinical adoption by integrating its Pathology Workbench software with Chronetyx's FDA-cleared and CE-IVD-marked Cyx Solid Tumor 505 test, automating tertiary analysis and significantly reducing turnaround times for NGS results. Collectively, these initiatives highlight how leading players are addressing bottlenecks in reimbursement, workflow automation, and biomarker expansion to accelerate precision oncology adoption.

NGS also plays a central role in immuno-oncology diagnostics. Tumor mutational burden (TMB), PD-L1 expression, and neoantigen profiling are increasingly used as biomarkers for response to immune checkpoint inhibitors. Evidence from advanced hepatocellular carcinoma (HCC) shows that TP53 mutations correlate with improved survival, while TERT and BRD4 mutations signal poor prognosis. Exome sequencing combined with proteomics helps identify which neoantigens are presented by the major histocompatibility complex (MHC), guiding personalized immunotherapy strategies.

Emerging diagnostic modalities such as liquid biopsy and single-cell sequencing are further reshaping the market. Liquid biopsy offers a non-invasive method to detect circulating tumor DNA (ctDNA) and monitor treatment resistance in real-time. Meanwhile, single-cell sequencing reveals intratumoral heterogeneity, identifying subclones that may drive resistance or metastasis. Together, these technologies address key limitations of conventional tissue biopsies and are poised to drive faster adoption of precision oncology.

A powerful enabler of these advancements is the integration of artificial intelligence (AI) and machine learning (ML). These tools can mine vast NGS and multi-omics datasets, uncovering hidden correlations that inform predictive modeling, treatment selection, and resistance mechanisms. AI-enhanced bioinformatics pipelines are expected to improve diagnostic accuracy, reduce turnaround times, and optimize clinical decision-making, making them a critical growth driver for the next generation cancer diagnostics market.

Nevertheless, significant challenges remain. Not all mutations detected are actionable, and many fall into a gray zone with uncertain clinical utility. Ethical considerations around incidental findings, patient consent, and data privacy further complicate adoption. To maximize the potential of NGS and related technologies, standardized guidelines, stronger evidence frameworks, and multidisciplinary collaboration across oncologists, geneticists, bioinformaticians, and ethicists are essential.

Overall, the market is evolving from single-modality genomic profiling to integrated, AI-powered, multi-omics solutions. With advances such as Illumina's FDA-approved CGP assays, QIAGEN's hematology-focused companion diagnostics, and GenomOncology's workflow automation partnerships, alongside the broader adoption of liquid biopsy and immuno-oncology biomarkers, the sector is positioned for substantial growth. However, its long-term trajectory will hinge on demonstrating clear clinical utility, cost-effectiveness, and improved patient outcomes in real-world practice.

Global Next Generation Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next generation cancer diagnostics market report based on technology, application, cancer type, function, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Next Generation Sequencing
  • qPCR & Multiplexing
  • LOAC & RT-PCR
  • Protein Microarrays
  • DNA Microarrays
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Function Outlook (Revenue, USD Million, 2021 - 2033)
  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Next Generation Cancer Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. Cancer Type Segment
      • 1.1.1.4. Function Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Next Generation Cancer Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology and Application Snapshot
  • 2.3. Cancer Type and Function Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Next Generation Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Exponentially decreasing cost of genetic sequencing
    • 3.4.2. Development of cluster chip technology and potential applications of CTC in cancer management
    • 3.4.3. Rising demand for preventive medicine & companion diagnostics
    • 3.4.4. Growing cancer incidence
  • 3.5. Market Restraint Analysis
    • 3.5.1. Requirement of expensive laboratory set-up for implementation of novel tests
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Next Generation Cancer Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Next Generation Cancer Diagnostics Market: Technology Movement Analysis
  • 4.2. Next Generation Sequencing
    • 4.2.1. Next Generation Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.3. qPCR & Multiplexing
    • 4.3.1. qPCR & Multiplexing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4. LOAC & RT-PCR
    • 4.4.1. LOAC & RT-PCR Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Protein Microarrays
    • 4.5.1. Protein Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.6. DNA Microarrays
    • 4.6.1. DNA Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Next Generation Cancer Diagnostics Market: Application Estimates & Trend Analysis

  • 5.1. Next Generation Cancer Diagnostics Market: Application Movement Analysis
  • 5.2. Biomarker Development
    • 5.2.1. Biomarker Development Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. CTC Analysis
    • 5.3.1. CTC Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Proteomic Analysis
    • 5.4.1. Proteomic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Epigenetic Analysis
    • 5.5.1. Epigenetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Genetic Analysis
    • 5.6.1. Genetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Next Generation Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 6.2. Lung Cancer
    • 6.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Breast Cancer
    • 6.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Colorectal Cancer
    • 6.4.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Cervical Cancer
    • 6.5.1. Cervical Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Next Generation Cancer Diagnostics Market: Function Estimates & Trend Analysis

  • 7.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 7.2. Therapeutic Monitoring
    • 7.2.1. Therapeutic Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Companion Diagnostics
    • 7.3.1. Companion Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Prognostics
    • 7.4.1. Prognostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Cancer Screening
    • 7.5.1. Cancer Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Risk Analysis
    • 7.6.1. Risk Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Next Generation Cancer Diagnostics Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Next Generation Cancer Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. CANADA
      • 8.2.3.1. Canada Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. MEXICO
      • 8.2.4.1. Mexico Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. GERMANY
      • 8.3.3.1. Germany Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. SPAIN
      • 8.3.4.1. Spain Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. FRANCE
      • 8.3.5.1. France Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. ITALY
      • 8.3.6.1. Italy Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. DENMARK
      • 8.3.7.1. Denmark Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. SWEDEN
      • 8.3.8.1. Sweden Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. NORWAY
      • 8.3.9.1. Norway Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. JAPAN
      • 8.4.2.1. Japan Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. CHINA
      • 8.4.3.1. China Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. INDIA
      • 8.4.4.1. India Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. SOUTH KOREA
      • 8.4.5.1. South Korea Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. THAILAND
      • 8.4.6.1. Thailand Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. AUSTRALIA
      • 8.4.7.1. Australia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. BRAZIL
      • 8.5.2.1. Brazil Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. ARGENTINA
      • 8.5.3.1. Argentina Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. SOUTH AFRICA
      • 8.6.2.1. South Africa Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. SAUDI ARABIA
      • 8.6.3.1. Saudi Arabia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. KUWAIT
      • 8.6.5.1. Kuwait Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. NEW PRODUCT LAUNCH
    • 9.2.2. PARTNERSHIPS
    • 9.2.3. ACQUISITION
    • 9.2.4. COLLABORATION
    • 9.2.5. FUNDING
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. JANSSEN PHARMACEUTICALS, INC.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. NOVARTIS AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. F. HOFFMANN-LA ROCHE LTD
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. KONINKLIJKE PHILIPS N.V.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. ABBOTT
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
    • 9.5.6. GE HEALTHCARE
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. THERMO FISHER SCIENTIFIC, INC.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AGILENT TECHNOLOGIES, INC. (DAKO)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. ILLUMINA, INC.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. QIAGEN
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. CEPHEID
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. OPKO HEALTH, INC.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. HOLOGIC, INC (GEN-PROBE)
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. PERKINELMER INC.
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives
    • 9.5.15. SYSMEX
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Financial Performance
      • 9.5.15.3. Product Benchmarking
      • 9.5.15.4. Strategic Initiatives
    • 9.5.16. MYRIAD GENETICS, INC.
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Financial Performance
      • 9.5.16.3. Product Benchmarking
      • 9.5.16.4. Strategic Initiatives
    • 9.5.17. ALMAC GROUP
      • 9.5.17.1. Company Overview
      • 9.5.17.2. Financial Performance
      • 9.5.17.3. Product Benchmarking
      • 9.5.17.4. Strategic Initiatives
    • 9.5.18. EXOSOME DIAGNOSTICS, INC.
      • 9.5.18.1. Company Overview
      • 9.5.18.2. Financial Performance
      • 9.5.18.3. Product Benchmarking
      • 9.5.18.4. Strategic Initiatives
    • 9.5.19. GENOMIC HEALTH, INC.
      • 9.5.19.1. Company Overview
      • 9.5.19.2. Financial Performance
      • 9.5.19.3. Product Benchmarking
      • 9.5.19.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 7 North America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 8 U.S next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 9 U.S next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 11 U.S. next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 12 Canada next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 13 Canada next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 15 Canada next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 16 Europe next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 17 Europe next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 18 Europe next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 19 Europe next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 20 Europe next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 21 UK next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 22 UK next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 23 UK next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 24 UK next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 25 Germany next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 26 Germany next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 27 Germany next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 28 Germany next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 29 France next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 30 France next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 31 France next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 32 France next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 33 Italy next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 34 Italy next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 35 Italy next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 36 Italy next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 37 Spain next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 38 Spain next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 39 Spain next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 40 Spain next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 41 Denmark next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Denmark next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 43 Denmark next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 44 Denmark next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 45 Sweden next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 46 Sweden next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 47 Sweden next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 48 Sweden next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 49 Norway next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 50 Norway next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 51 Norway next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 52 Norway next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 54 Asia Pacific next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 58 China next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 59 China next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 60 China next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 61 China next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 62 Japan next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 63 Japan next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 64 Japan next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 65 Japan next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 66 India next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 67 India next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 68 India next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 69 India next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 70 South Korea next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 71 South Korea next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 72 South Korea next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 73 South Korea next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 74 Australia next generation cancer diagnostics market, by technology 2021 - 2033 (USD Million)
  • Table 75 Australia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 76 Australia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 77 Australia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 78 Thailand next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 79 Thailand next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 80 Thailand next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 81 Thailand next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 82 Latin America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 83 Latin America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 84 Latin America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 85 Latin America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 86 Latin America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 87 Brazil next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 88 Brazil next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 89 Brazil next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 90 Brazil next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 91 Mexico next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 92 Mexico next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 93 Mexico next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 94 Mexico next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 95 Argentina next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 96 Argentina next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 97 Argentina next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 98 Argentina next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 99 Middle East & Africa next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 100 Middle East & Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 101 Middle East & Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 102 Middle East & Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 104 South Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 105 South Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 106 South Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 107 South Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 112 UAE next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 113 UAE next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 114 UAE next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 115 UAE next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
  • Table 116 Kuwait next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 117 Kuwait next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 118 Kuwait next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 119 Kuwait next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global next generation cancer diagnostics market - Key market driver analysis
  • Fig. 7 Global next generation cancer diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global next generation cancer diagnostics market - Porter's analysis
  • Fig. 10 Global next generation cancer diagnostics market - PESTEL analysis
  • Fig. 11 Global next generation cancer diagnostics market technology outlook key takeaways
  • Fig. 12 Global next generation cancer diagnostics market: Technology movement analysis
  • Fig. 13 Next generation sequencing market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 qPCR & multiplexing market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 LOAC & RT-PCR market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Protein microarrays market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 DNA microarrays market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Global next generation cancer diagnostics market application outlook key takeaways
  • Fig. 19 Global next generation cancer diagnostics market: application movement analysis
  • Fig. 20 Biomarker development market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 CTC analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Proteomic analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Epigenetic analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Global next generation cancer diagnostics market cancer type outlook key takeaways
  • Fig. 25 Global next generation cancer diagnostics market: Cancer type movement analysis
  • Fig. 26 Lung cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Breast cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Cervical cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Global next generation cancer diagnostics market function outlook key takeaways
  • Fig. 32 Global next generation cancer diagnostics market: Function movement analysis
  • Fig. 33 Therapeutic monitoring market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Companion diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Prognostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Cancer screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Risk analysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Global next generation cancer diagnostics market: Regional movement analysis
  • Fig. 40 North America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 42 Canada next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 46 France next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 48 Italy next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 51 Norway next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 54 China next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 55 India next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 61 Mexico next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 63 MEA next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 64 South Africa next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 65 Saudi Arabia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 66 UAE next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 67 Kuwait next generation cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 68 Strategy framework